Background. Patients with high tacrolimus clearance eliminate more drug within a dose interval compared with those with low clearance. Delays in dosing time will result in transient periods of lower concentrations in high versus low clearance patients. Transient subtherapeutic tacrolimus concentrations may induce acute rejection episodes. Methods. A retrospective study in all renal transplant patients treated with tacrolimus at our center from 2009 to 2013 was conducted. The association between individually estimated tacrolimus clearance (daily tacrolimus dose [mg]/trough concentration [μg/L]) and biopsy-proven acute rejection (BPAR) the first 90 days posttransplantation was investigated. Results. In total, 638 patients treated with oral tacrolimus were included in the analysis. Eighty-five (13.3%) patients experienced BPAR. Patients were stratified into 4 groups per their estimated clearance. The patients in the high clearance group had significantly higher incidence of BPAR (20.6%) with a hazard ratio of 2.39 (95% confidence interval, 1.30-4.40) compared with the low clearance group. Clearance estimate (as a continuous variable) showed a hazard ratio of 2.25 (95% confidence interval, 1.70-2.99) after adjusting for other risk factors. There were no significant differences in neither trough concentrations the first week after transplantation nor time to target trough concentration between patients later experiencing BPAR or not. Conclusions. High estimated clearance is significantly associated with increased risk of BPAR the first 90 days posttransplantation and may predict an increased risk of rejection in the early phase after renal transplantation.
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(Transplantation 2017;101: e273-e279) E ven with the current immunosuppressive regimens, 10% to 20% of renal transplant recipients develop early acute rejections. 1, 2 Tacrolimus is the cornerstone in the immunosuppressive regimen after renal transplantation.
Underdosing of tacrolimus increases the risk of acute rejection and development of de novo donor-specific antibodies. 3 Overdosing on the other hand is associated with side effects, such as renal toxicity and posttransplantation diabetes mellitus. 4, 5 Hence, both overdosing and underdosing are potentially detrimental for long-term graft survival. To assure individually optimal doses of tacrolimus, therapeutic drug monitoring using tacrolimus trough concentration measurements is routinely applied at most transplant centers. 6 Tacrolimus is a critical dose drug with a high intraindividual and interindividual pharmacokinetic variability. 7, 8 High intrapatient variability of tacrolimus has in several studies been related to impaired long-term outcome. [9] [10] [11] [12] [13] The high intrapatient variability may be due to many factors, such as comedication, nonadherence, and food.
14 Nonadherence in renal transplant recipients is estimated to be approximately 20% to 25% and is associated with impaired long-term outcomes. [15] [16] [17] [18] Almost every transplant patient will in daily life take their immunosuppressive drugs at irregular time intervals or even miss a dose at some occasions. Saint-Marcoux et al 19 investigated the pharmacokinetic consequences of a missed or delayed dose of tacrolimus using a population pharmacokinetic model. They showed that missing 1 dose would lead to a potentially clinically relevant temporary lower tacrolimus exposure (area under the curve) in patients with high tacrolimus clearance as compared with those with low clearance. Such short temporary subtherapeutic immunosuppressive episodes may trigger the immune system and potentially lead to an acute rejection episode or promote development of de novo donor-specific antibodies.
The aim of the present analysis was to investigate the association between individual tacrolimus clearance, controlled for actual trough concentrations obtained, and incidence of biopsy-proven acute rejection (BPAR) the first 90 days after renal transplantation.
MATERIALS AND METHODS
A single-center, retrospective study was conducted. Data from all adult tacrolimus-treated renal recipients followed up for a minimum of 8 weeks posttransplantation at Oslo University Hospital Rikshospitalet, Norway, transplanted between January 2009 and December 2013 were included.
Oral tacrolimus was initiated on the day of transplantation, starting with 0.04 mg/kg twice daily in standard-risk patients and 0.05 mg/kg twice daily in high-risk patients. Therapeutic drug monitoring was applied and dose adjustments aimed to reach target whole blood trough concentrations of 3 to 7 μg/L in standard risk patients, 20 and 8 to 12 μg/L (days 0-30) and 6 to 10 μg/L (after day 30) in highrisk patients. High immunological risk was defined as presence of donor-specific antibodies, panel-reactive antibodies (PRA) greater than 20% at transplantation or ABO incompatibility between donor and recipient. Before 2012, allocation to either tacrolimus or cyclosporine was based on an algorithm (patients with diabetes and those older than 55 years at the time of transplantation received cyclosporine) resulting in a roughly 50:50 distribution. From January 2012, all patients received tacrolimus except recipients already receiving cyclosporine therapy before retransplantation.
Induction treatment consisted of 20 mg intravenous basiliximab on day 0 and 4 after transplantation and 250 mg (standard risk) or 500 mg (high risk) intravenous methylprednisolone on day 0. A single dose of 375 mg/m 2 rituximab was given to DSA-positive and ABO-incompatible patients 4 weeks before transplantation (living donor) or at transplantation (deceased donor). From day 0 to 4, 400 mg/kg IVIg were given to DSA-positive patients, whereas ABO-incompatible patients were given a single dose of 500 mg/kg IVIg at transplantation. Patients with PRA greater than 20% which were DSA-negative were given antithymocyte globulin induction (Genzyme) at time of transplantation.
As maintenance therapy in addition to tacrolimus, all patients received 750 mg oral mycophenolate mofetil twice daily and prednisolone once daily, initiated at 20 mg (80 mg in high-risk patients), and tapered to 10 mg at 4 weeks in standard risk recipients and 8 weeks in immunologic highrisk recipients.
The clinical follow-up after transplantation was performed at the transplant center for the first 8 to 10 weeks, after which the patients were transferred to their local nephrology unit. If there was suspicion of rejection, patients were referred back to the transplant center for an ultrasound-guided graft biopsy. Tacrolimus trough concentrations were measured 3 to 4 times per week early after transplantation and were gradually reduced to once a week after about 8 weeks. All patients were routinely scheduled for a comprehensive investigation at 8 weeks posttransplantation. During this investigation, both measured glomerular filtration rate (iohexol plasma clearance) and oral glucose tolerance were assessed.
The study was approved by the Regional Committee for Medical Research Ethics and was performed in accordance with the declaration of Helsinki. The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the "Declaration of Istanbul on Organ Trafficking and Transplant Tourism." All patients signed a written informed consent at the time of transplantation.
Analysis of Tacrolimus Trough Concentrations
All blood samples for tacrolimus whole-blood concentration measurement were drawn immediately before the morning dose. Concentrations were determined using the chemiluminescent microparticle immunoassay (analyzed on the Architect Instrument; Abbott Laboratories, Abbot Park, IL). 21 The assay was consistently applied throughout the study period. The lower limit of quantification was 1.0 μg/L. The coefficients of variation of the between series imprecision were 6% at 2 μg/L and 3.5% at 7.2 μg/L, respectively.
Acute Rejection
In this study, only BPARs are reported. Suspicion of acute rejection was based on an unexplained increase in serum creatinine greater than 20 %. If there was suspicion a renal core biopsy was obtained and classified according to the Banff criteria. 22 Between 6 and 8 weeks posttransplant, a protocol biopsy was scheduled and subclinical acute rejections diagnosed in these biopsies were also included in the final analyses. Rejections were treated with intravenous methylprednisolone given in daily pulses introduced at 500 mg, and followed by doses of 250 mg/d for up to 3 days. Oral prednisolone doses were also increased to 30 mg/d and were tapered by 5 mg every other week. Steroid-resistant rejections or vascular rejections were treated with CD3 monitored intravenous antithymocyte globulin (Genzyme). 23 
Estimation of Tacrolimus Apparent Oral Clearance
The ability of each patient to eliminate tacrolimus was estimated by dividing the total daily tacrolimus dose with the morning trough concentrations (daily dose [mg]/trough concentration [μg/L]). For this estimate the mean of all wholeblood tacrolimus concentrations obtained from 7 days before 2 days after the in-depth investigation day performed 8 weeks after transplantation were used. For simplicity, this variable will be referred to as "clearance," and reported without units
), throughout the manuscript. Rejection treatment with intravenous methylprednisolone may induce cytochrome P450 (CYP) enzymes, which in turn may lead to an overestimation of tacrolimus clearance. 24 Clearance for BPAR patients was therefore also estimated from 3 tacrolimus doses and trough concentrations before the day of initiation of acute rejection treatment.
Statistical Analysis
The outcome in the present analysis was the association between tacrolimus clearance and BPAR the first 90 days after transplantation. Patients were stratified into 4 groups (low, below average, above average, and high) according to the quartiles of estimated tacrolimus clearance. A KaplanMeier analysis with log-rank test and a Cox regression analysis comparing hazard ratio (HR) of the below average, above average and high clearance groups versus the low clearance group were performed.
To further assess the independent effect of potential risk factors on acute rejection, a multivariate Cox-regression was performed using time to first BPAR as a main outcome. Estimated clearance (on a continuous scale) and other clinically important risk factors, such as delayed graft function (DGF) (dialysis treatment first 7 days after transplantation), 1, 2 HLA-DR mismatch (1 or 2 mismatches), 2 immunologic high-risk, 25 and sex, were included in the model.
Receiver operator characteristic curve analyses were performed to identify clearance cutoffs for patients at increased risk of BPAR the first 90 days after transplantation. One cutoff was made by finding the clearance value with the highest sum of specificity and sensitivity, and another was made by its possibility to detect 20% of the patients experiencing BPAR. The prevalence of BPAR was used to calculate the positive predictive value (PPV) and negative predictive value (NPV).
Differences between continuous variables were analyzed with the Student t test, and differences between categorical variables with the χ 2 test. P values less than 0.05 were considered to be statistically significant. All analyses were done in R version 3.2.3.
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RESULTS
Patients
A total of 1198 adult patients were transplanted from January 2009 to December 2013, and 717 of these received tacrolimus. A total of 465 patients received cyclosporine, 4 received an investigational study drug and 3 received everolimus instead of tacrolimus. Eight patients had missing data and 1 patient had a nonfunctional transplant. Seventy-nine of the 717 tacrolimus-treated patients (11.0%) were early transferred to their local hospital and did not attend the 8-week comprehensive investigation at our transplant center. Distributions of selected demographical data of the remaining 638 patients included in the analysis are shown in Table 1 . During the first 90 days posttransplantation a total of 85 (13.3%) patients experienced BPAR, after a median (interquartile range) time of 8 days (5-31). Sixty-five (12.1%) of the 537 standard, and 20 (19.8%) of 101 high immunological risk patients experienced BPAR, respectively.
BPAR Risk Factors
The recipients were categorized into low, below average, above average, and high tacrolimus clearance groups with mean estimated clearance of 0.38 ± 0.10, 0.62 ± 0.06, 0.85 ± 0.08, and 1.48 ± 0.54 units, respectively. Cox regression with the categorical clearance groups showed that the below average group had a HR of 0.87 (95% confidence interval [CI], 0.41-1.83; P = 0.72), above average HR of 1.65 (95% CI, 0.86-3.14; P = 0.13 and the high clearance group had a HR of 2.39 (95% CI, 1.30-4.40; P < 0.006) for BPAR the first 90 days posttransplant. All groups were compared to the low clearance group. This is depicted visually in a Kaplan-Meier plot in Figure 1 . Table 2 shows the results from the multivariate Cox analysis. Estimated tacrolimus clearance, DGF, immunological high risk, and male sex were all shown to be independent risk factors for BPAR in the multivariable model. A 1 unit increase in the continuous clearance estimate showed a HR of 2.25 (95% CI, 1.70-2.99; P < 0.001) for experiencing BPAR.
There were no differences in mean tacrolimus trough concentrations at week 1 or 8 after transplantation between patients with or without BPAR in neither standard-risk nor high immunological risk recipients (Table 3 ). The mean trough concentrations before BPAR-diagnosis were within the therapeutic range for both the standard-risk and high immunological risk patients (Table 3) .
Time to reach target tacrolimus concentrations (ie, >3.0 μg/L for standard immunological risk and >8.0 μg/L for high immunological risk patients) for the low, below average, above average, and high clearance groups were 1.40 ± 0.79, 2.06 ± 2.48, 2.44 ± 3.10, and 3.06 ± 4.14 days, respectively. There was no difference in time to reach target for patients experiencing and not experiencing BPAR (2.22 ± 2.29 vs 2.24 ± 3.04 days, P = 0.95).
Receiver operator characteristic analysis showed a clearance cutoff value of 0.71 units to maximise the sum of sensitivity and specificity. The sensitivity was 68% and specificity 48%. With a prevalence of BPAR of 13%, the PPV and NPV were 18% and 91%, respectively, and 323 of the 638 patients had a clearance above 0.71 units. The BPAR-free survival curve of this risk stratification is shown in Figure 2 . An optimized cutoff for detecting 20% of patients experiencing BPAR was 1.45 units. The PPV was 30% and the corresponding NPV was 88%. Applying this cutoff identified 17 (20%) of the 85 patients with BPAR. The BPAR-free survival curve is shown in Figure 3 .
DISCUSSION
The major finding in this study was that renal transplant recipients with high tacrolimus clearance had a higher risk of having an acute rejection episode in the early phase after renal transplantation. A plausible explanation could have been that patients with high tacrolimus clearance had lower trough concentrations, but no such difference was identified between recipients experiencing BPAR or no-BPAR in neither standard-risk nor in high immunological risk patients. Like what have been shown in previous studies, we found that DGF, male sex and immunological high risk were independent risk factors for acute rejection in the early phase after transplantation. 1 The multivariate analysis showed that a 1-unit higher estimated clearance resulted in an independent doubling of the risk of BPAR the first 90 days posttransplantation, for example, a patient receiving a daily tacrolimus dose of 7.5 mg to reach a trough concentration of 5.0 μg/L will have more than twice the risk of BPAR compared to a patient receiving a dose of 2.5 mg to achieve the same trough concentration.
The time to reach the target trough concentrations was different between the clearance groups. Patients in the low clearance group reached the target trough concentration range faster than the patients in the other clearance groups. Theoretically, this could have been an explanation for the difference in risk of BPAR observed between the groups. However, there was no significant difference in time to reach the target concentrations between patients experiencing, and not experiencing BPAR. The induction therapy including basiliximab may be sufficient to cover this initial small difference in target achievement.
To our knowledge, this is the first study investigating the association between patients' individual tacrolimus clearance and clinical outcomes after renal transplantation. Based on the publication by Saint-Marcoux et al, 19 it is likely that patients with high tacrolimus clearance compared with patients with low clearance have a higher risk of triggering the immune system with a delayed or skipped dose of tacrolimus. Unfortunately, the adherence data from our patients are lacking. However, the median time from transplantation to BPAR in the present study was only 8 days (Figure 1) . In this period, all patients were hospitalized in the surgical ward with an anticipated adherence close to 100%. Nonadherence is Mean tacrolimus concentrations in standard-risk and high immunological-risk patients therefore not likely to be the main reason for the findings in the present study. A high estimated clearance may also be due to a low oral bioavailability which generates a higher-dosage need to achieve target trough concentrations. An alternative hypothesis to our findings is that there is a correlation between tacrolimus oral bioavailability and intralymphocyte concentrations (site of immunosuppressive action). Many of the same mechanisms that lead to a low bioavailability (eg, P-glycoprotein and CYP-enzymes) are also present in lymphocytes and might lead to a low intralymphocyte tacrolimus concentration. 27 Disregarding the mechanism behind the present findings, individual clearance estimates would be a fast and easily obtainable clinical risk factor to identify recipients that need special attention with regards to tacrolimus therapy. Setting a cutoff at about 1.5 units has the potential to identify a significant proportion of the patients with increased risk of acute rejection. A potential for optimising therapy in high-risk patients identified by high clearance estimates may be intensified information and education on the importance of strict adherence, or even switching these patients to an extended release tacrolimus formulation to minimize episodes of under immunosuppression. 28 The 1.5-unit cutoff has a PPV of 30%, which is rather low. But our suggested interventions for an individual patient, in case of a clearance estimate above the cutoff, are noninvasive. In the event of a false-positive test, the patient will be more thoroughly followed up, which is not associated with any increased risk for the individual patient.
CYP3A5 genotype is associated with tacrolimus clearance and patients expressing the functional protein need about twice as high dose to obtain the same trough concentrations as patients not expressing functional CYP3A5. 29 A previous publication from our center 30 found that 15% of our patient population express functional CYP3A5, which is in concordance with other estimates from white populations. 31 Unfortunately, we do not have CYP3A5 genotype data on the patients included in the present analysis, which is an obvious limitation to our study. However, continuous clearance estimates from all patients were used in the multivariate analysis which means that a relative increase in clearance gives an increased risk in every patient. Therefore, will the vast majority of patients that do not express functional CYP3A5 still have the same increased of risk of BPAR associated with high clearance as those expressing functional CYP3A5? Approximately half of the patients had an estimated clearance above 0.71 units and had a higher risk of BPAR compared to patients with clearance below this threshold as shown in Figure 2 . Thus, it is unlikely that the effect shown in the present study could be explained solely by CYP3A5-genotype.
Both ethnicity and concomitant intake of drugs influencing CYP3A are known factors that may influence tacrolimus pharmacokinetics. 32, 33 The ethnicity of patients transplanted at our center is not registered. The population is very homogenous, with most patients being of white origin. Similarly, we do not have data on comedications given to the patients included in the current study. The influence of CYP3A inducers or inhibitors as well as the patients' ethnicity is however a minor problem for the present analysis because the phenotype will be reflected by the clearance estimates.
Glucocorticoid doses given for acute rejection treatment may have biased the results in the present analysis because on tacrolimus clearance via induction of CYP-enzymes. 24 The results remained however similar, irrespective of whether clearance was estimated from the 8-week investigational day or the day before initiation of acute rejection treatment.
The strengths of this study include many patients transplanted at a single center that underwent uniform clinical treatment and investigations.
The study has several limitations, some of which have been addressed in previous sections. The majority of patients are followed at our transplant center for 8 to 10 weeks posttransplant, but 79 patients were transferred to local hospitals at an earlier time. We cannot rule out that this has introduced a bias in the data sample, but the decision to transfer patients is not based on any known factors that directly influence either tacrolimus clearance or risk of acute rejection.
All tacrolimus concentrations used in this study were measured with the chemiluminescent microparticle immunoassay method. This immunoassay measure on average 18% higher tacrolimus concentrations than liquid chromatography combined with tandem mass spectrometry (which is considered the criterion standard), mainly due to cross-reactivity with tacrolimus metabolites. 34 This overestimation of tacrolimus concentrations has not affected the results in this study because the immunoassay was consistently applied through the entire study period. However, somewhat different cutoff values will be expected if using other analytical methods. This should be considered before applying our results.
To increase the generalizability of our results, we included all standard-and high-risk patients transplanted in the period between January 2009 and December 2013 treated with tacrolimus. Because the standard-and high-risk patients have different target trough concentrations, the Cox-regression analysis did not include trough concentration as a variable. In a subanalysis of the 537 standard risk patients, we performed a similar multivariate Cox-regression as presented in Table 2 , also including mean trough concentrations days 1 to 7 posttransplant for all patients ( Table S1 , SDC, http:// links.lww.com/TP/B443). This model overall showed the same results as seen in the whole population and lower tacrolimus trough concentrations were not associated with increased risk of BPAR.
CONCLUSION
Estimated high tacrolimus clearance is significantly and independently associated with an increased risk of BPAR the first 90 days after renal transplantation in a real-life setting with both standard-risk and high immunological-risk patients. A cutoff value of 1.5 units can identify patients with increased risk of acute rejection in the early phase after transplantation. The causality of this association is not known, CYP3A5 genotype may potentially explain part of the association, though expression of CYP3A5 may not fully substitute high estimated clearance as a risk factor.
